IN2014CH00247A - - Google Patents

Download PDF

Info

Publication number
IN2014CH00247A
IN2014CH00247A IN247CH2014A IN2014CH00247A IN 2014CH00247 A IN2014CH00247 A IN 2014CH00247A IN 247CH2014 A IN247CH2014 A IN 247CH2014A IN 2014CH00247 A IN2014CH00247 A IN 2014CH00247A
Authority
IN
India
Prior art keywords
novel
dolutegravir
preparation
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
Other languages
English (en)
Inventor
Chava Satyanarayana
Ramanjaneyulu Gorantla Seeta
Lakshmi Narasimha Rao Dammalapati Venkata
Bushan Kotala Mani
Aduri Ravindra
Original Assignee
Laurus Labs Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurus Labs Private Ltd filed Critical Laurus Labs Private Ltd
Priority to ES15740288T priority Critical patent/ES2770050T3/es
Priority to US15/113,080 priority patent/US9856271B2/en
Priority to EP15740288.4A priority patent/EP3096763B1/en
Priority to PCT/IB2015/000048 priority patent/WO2015110897A2/en
Priority to IN247CH2014 priority patent/IN2014CH00247A/en
Priority to PCT/IN2015/000040 priority patent/WO2015111080A2/en
Publication of IN2014CH00247A publication Critical patent/IN2014CH00247A/en
Priority to US15/809,151 priority patent/US10301321B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
IN247CH2014 2014-01-21 2015-01-20 IN2014CH00247A (ar)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES15740288T ES2770050T3 (es) 2014-01-21 2015-01-20 Nuevo procedimiento para la preparación de dolutegravir y sus sales farmacéuticamente aceptables
US15/113,080 US9856271B2 (en) 2014-01-21 2015-01-20 Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
EP15740288.4A EP3096763B1 (en) 2014-01-21 2015-01-20 Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
PCT/IB2015/000048 WO2015110897A2 (en) 2014-01-21 2015-01-20 Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
IN247CH2014 IN2014CH00247A (ar) 2014-01-21 2015-01-20
PCT/IN2015/000040 WO2015111080A2 (en) 2014-01-21 2015-01-21 Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
US15/809,151 US10301321B2 (en) 2014-01-21 2017-11-10 Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN247CH2014 IN2014CH00247A (ar) 2014-01-21 2015-01-20

Publications (1)

Publication Number Publication Date
IN2014CH00247A true IN2014CH00247A (ar) 2015-08-14

Family

ID=53682060

Family Applications (1)

Application Number Title Priority Date Filing Date
IN247CH2014 IN2014CH00247A (ar) 2014-01-21 2015-01-20

Country Status (5)

Country Link
US (2) US9856271B2 (ar)
EP (1) EP3096763B1 (ar)
ES (1) ES2770050T3 (ar)
IN (1) IN2014CH00247A (ar)
WO (2) WO2015110897A2 (ar)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216996B2 (en) 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
NO2865735T3 (ar) 2013-07-12 2018-07-21
NO2717902T3 (ar) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
CZ201599A3 (cs) * 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
EP3394069B1 (en) * 2015-12-21 2019-05-22 Lupin Limited Process for the preparation of hiv integrase inhibitors
CN105699509B (zh) * 2016-01-23 2018-08-31 河北科技大学 一种3-氨基丁醇对映异构体的分离检测方法
CN106565747A (zh) * 2016-11-10 2017-04-19 顾世海 一种制备度鲁特韦的新方法
EP3661940A1 (en) 2017-09-07 2020-06-10 Cipla Limited New polymorphs of dolutegravir sodium
US11286262B2 (en) 2017-10-06 2022-03-29 Shionogi & Co., Ltd. Stereoselective process for preparing substituted polycyclic pyridone derivatives
CN107935881B (zh) * 2017-12-11 2020-06-26 浙江朗华制药有限公司 一种n-[(2,4-二氟苯基)甲基]-4-甲氧基-3-氧代丁酰胺的制备方法
EP3866803A1 (en) * 2018-10-19 2021-08-25 Virginia Commonwealth University Novel pyrrole and pyridone derivatives and uses thereof
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
CN110294705A (zh) * 2019-07-25 2019-10-01 浙江沙星科技有限公司 一种度鲁特韦关键中间体的合成方法
CN111620891B (zh) * 2020-05-27 2023-07-14 上海启讯医药科技有限公司 一种多替拉韦关键中间体溶剂化物多晶型物及其制备方法和用途
CN116783167A (zh) 2020-11-17 2023-09-19 盐野义制药株式会社 新颖吖啶鎓盐及其制造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2437268T3 (es) * 2005-04-28 2014-01-09 Viiv Healthcare Company Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH
EP2320908B9 (en) * 2008-07-25 2014-06-18 VIIV Healthcare Company Dolutegravir Prodrugs
WO2010011819A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
JP5572168B2 (ja) 2008-12-11 2014-08-13 ビーブ・ヘルスケア・カンパニー カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
KR101847887B1 (ko) * 2008-12-11 2018-04-11 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
BR112013002461A2 (pt) * 2010-08-05 2016-05-24 Shionogi & Co método para produzir um composto, e, cristal de um composto
EP3016935B1 (en) 2013-07-04 2018-09-05 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
WO2015177537A1 (en) 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
WO2016092527A1 (en) 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US10975096B2 (en) 2014-06-20 2021-04-13 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives

Also Published As

Publication number Publication date
EP3096763A2 (en) 2016-11-30
US20160333026A1 (en) 2016-11-17
WO2015110897A2 (en) 2015-07-30
US9856271B2 (en) 2018-01-02
EP3096763B1 (en) 2019-12-25
ES2770050T3 (es) 2020-06-30
US20180155364A1 (en) 2018-06-07
WO2015110897A3 (en) 2015-12-03
EP3096763A4 (en) 2017-06-28
US10301321B2 (en) 2019-05-28
WO2015111080A2 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
IN2014CH00247A (ar)
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
JO3487B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
IN2013MU00646A (ar)
IN2013MU00848A (ar)
MX2016015464A (es) Composicion farmaceutica oral de isotretinoina.
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
HUE058627T2 (hu) Új eljárás nagy tisztaságú prosztaglandinok elõállítására
EP3099304A4 (en) Novel therapeutics for the treatment of glaucoma
IN2013MU03070A (ar)
MX2017011389A (es) Proceso para la preparacion de 3-cloro-2-vinilfenilsulfonatos.
MA40312A (fr) Composition pharmaceutique orale d'isotrétinoïne
MX2016015624A (es) Proceso para la preparacion de derivados de tiazol.
IN2014MU01192A (ar)
EP3092217A4 (en) A novel process for preparation of indacaterol or its pharmaceutically acceptable salts
IN2014MU00195A (ar)
IN2013MU01111A (ar)
MA40447A (fr) Composition pharmaceutique orale d'isotrétinoïne
PL3223799T3 (pl) Sposób otrzymywania kompozycji składnik farmaceutyczny-polimer
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.
MX2016015623A (es) Proceso para la preparacion de derivados dihidroisoxazol.
IN2014MU00194A (ar)
IN2014MU01196A (ar)